Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013.
Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients having had BJI or PJI treated with daptomycin | patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| patients having had BJI or PJI treated with daptomycin | Other | patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK |
| Measure | Description | Time Frame |
|---|---|---|
| rate of patients having had a PJI or BJI treated by daptomycin | proportion of patients treated by daptomycin | between 2010 and 2020 |
| description of BJI/PJI | type of BJI or PJI | between 2010 and 2020 |
| description of patients | comorbidites | between 2010 and 2020 |
| description of adverse event | type of adverse event | between 2010 and 2020 |
| rate of patients having had an adverse event | proportion of patients having had an adverse event under daptomycin | between 2010 and 2020 |
| Evalutation of the adverse event due to daptomycin : dosage of daptomycine | description of the use of daptomycine : dosage | between 2010 and 2020 |
| Evalutation of the adverse event due to daptomycin : duration of daptomycine | description of the use of daptomycine : duration | between 2010 and 2020 |
| Evalutation of the adverse event due to daptomycin : daptomycine plasma clearance | mean daptomycine plasma clearance (unit, liters per hour) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients managed at the CRIOAc Lyon who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tristan Ferry, Md,PhD | Contact | 04 26 73 29 38 | tristan.ferry@chu-lyon.fr | |
| Eugenie Mabrut, CRA | Contact | 04 26 73 29 38 | eugenie.mabrut@chu-lyon.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Recruiting | Lyon | 69004 | France |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011657 | Pulmonary Eosinophilia |
| D012206 | Rhabdomyolysis |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D017681 | Hypereosinophilic Syndrome |
| D004802 | Eosinophilia |
Not provided
Not provided
| ID | Term |
|---|---|
| D017576 | Daptomycin |
| ID | Term |
|---|---|
| D010456 | Peptides, Cyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D055666 | Lipopeptides |
Not provided
Not provided
Not provided
Not provided
Not provided
| between 2010 and 2020 |
| Evalutation of the adverse event due to daptomycin : daptomycine volume distribution | mean daptomycine volume of distribution (unit, liters) | between 2010 and 2020 |
| D007960 |
| Leukocyte Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D008055 |
| Lipids |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |